A LYSA Phase lb Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features

Sarkozy Clementine; Morschhauser Franck; Dubois Sydney; Molina Thierry; Michot Jean Marie; Cullieres-Dartigues Peggy; Suttle Benjamin; Karlin Lionel; Le Gouill Steven; Picquenot Jean-Michel; Dubois Romain; Tilly Herve; Herbaux Charles; Jardin Fabrice; Salles Gilles; Ribrag Vincent

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A LYSA Phase lb Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features

【24h】

A LYSA Phase lb Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features

机译：Tazemetostat（EPZ-6438）的Lysa相磅研究（EPZ-6438）加上新诊断的弥漫性大B细胞淋巴瘤（DLBCL）的患者R-Chec，预后特征差

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: The histone-methyl transferase EZH2, catalytic subunit of the PRC2 complex involved in transcriptional regulation, is mutated in approximately 25% of germinal center B-cell lymphomas. Aberrant proliferative dependency on EZH2 activity can be targeted by the orally available EZH2 inhibitor tazemetostat (EPZ-6438). We report the results of the phase lb tazemetostat plus R-CHOP combination (NCT02889523), in patients 60 to 80 years of age with newly diagnosed diffuse large B-cell lymphoma.

机译：目的：组蛋白 - 甲基转移酶EZH2，参与转录调节的PRC2复合物的催化亚基，在大约25％的生发中心B细胞淋巴瘤中突变。对EZH2活性的异常增殖依赖性可以由口服的EZH2抑制剂Tazemetostat（EPZ-6438）靶向。我们报告了第1B届Tazemetostat加R-Chec组合（NCT02889523）的结果，患者60至80岁，新诊断缩小大B细胞淋巴瘤。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2020年第13期|共9页
作者
Sarkozy Clementine; Morschhauser Franck; Dubois Sydney; Molina Thierry; Michot Jean Marie; Cullieres-Dartigues Peggy; Suttle Benjamin; Karlin Lionel; Le Gouill Steven; Picquenot Jean-Michel; Dubois Romain; Tilly Herve; Herbaux Charles; Jardin Fabrice; Salles Gilles; Ribrag Vincent;
展开▼
作者单位

Claude Bernard Univ Charles Merieux Lyon Fac 1 INSERM 1052 Lyon France;

U1245 Ctr Hosp RU Lille Dept Hematol Lille France;

U918 Ctr Henri Becquerel Dept Hematol Rouen France;

Univ Paris Necker Enfants Malad Hosp AP HP Dept Pathol Paris France;

Univ Paris Saclay Gustave Roussy Dept Hematol INSERM U1170 Villejuif France;

Univ Paris Saclay Gustave Roussy Dept Pathol INSERM U1170 Villejuif France;

qPharmetra Durham NC USA;

Ctr Hosp Lyon Sud Hosp Civils Lyon Dept Hematol Pierre Benite France;

CHU Nantes Dept Hematol Nantes France;

U918 Ctr Henri Becquerel Dept Pathol Rouen France;

Ctr Hosp RU Lille Dept Pathol Lille France;

U918 Ctr Henri Becquerel Dept Hematol Rouen France;

U1245 Ctr Hosp RU Lille Dept Hematol Lille France;

U918 Ctr Henri Becquerel Dept Hematol Rouen France;

Claude Bernard Univ Charles Merieux Lyon Fac 1 INSERM 1052 Lyon France;

Univ Paris Saclay Gustave Roussy Dept Hematol INSERM U1170 Villejuif France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A LYSA Phase lb Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features [J] . Sarkozy Clementine, Morschhauser Franck, Dubois Sydney, Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第13期

机译：Tazemetostat（EPZ-6438）的Lysa相磅研究（EPZ-6438）加上新诊断的弥漫性大B细胞淋巴瘤（DLBCL）的患者R-Chec，预后特征差
2. Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy [J] . Ian W. Flinn, Jack Erter, Davey B. Daniel, The oncologist . 2019,第8期

机译：对老年人患者的肺蛋白和奥塔姆姆人类对新诊断的弥漫性大B细胞淋巴瘤的II期研究
3. Responses and Cardiotoxicity with R-CDOP and R-CHOP Observed in Frontline Therapy for Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Randomized Phase-IV Study from Multiple Centers in China [J] . Feng Lili, Chu Xiaoxia, Zhao Hongguo, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：对初级弥漫性大B细胞淋巴瘤（DLBCL）和卵泡淋巴瘤（FL）的患者前线治疗中观察到R-CDOP和R-Chect的反应和心脏毒性：来自中国多个中心的随机期 - IV研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma [O] . Mu-Chen Zhang, Ying Fang, Li Wang, 2020

机译：在老年诊断弥漫性大型B细胞淋巴瘤的老年患者中Tucidinostat加入R-Chec患者的临床疗效和分子生物标志物。
6. R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS [O] . T. Lamy, G. Damaj, P. Soubeyran, 2017

机译：r-chop +/-放射治疗在非笨重的有限阶段扩散大b细胞淋巴瘤（DLBCL）：前瞻性随机阶段III 02-03从Lysa / Goelams试验的最终结果

A LYSA Phase lb Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features

摘要

著录项

相似文献

相关主题

期刊订阅